VivoSim Labs, Inc. VIVS
0.15 USD +0.01 (+5.99%)
At closeNov 4, 2026, 5:19 PM EST
0.15 0.00 -0.46%
After hours · Nov 4, 5:19 PM ET
0.1445 Day range 0.155
0.14 52-week range 3.40
- YTD
- -91.59%
- 1 year
- -93.08%
- Market cap
- 2.52M
- EPS (ttm)
- -4.47
- YTD return
- -91.59%
- 1-year return
- -93.08%
- Volume
- 535.57K
- Avg volume
- 2.65M
- Open
- 0.155
- Previous close
- 0.1436
- Day's range
- 0.1445 – 0.155
- 52-week range
- 0.14 – 3.40
1M -0.0598 (-28.48%)
Financials — quick view
VIVS Revenue — quarterly 18.00K
VIVS Net income — quarterly -1.34M
VIVS EPS — quarterly -0.25
News
VivoSim Labs Partners With Chemveda Life Sciences To Test, Screen AI-Derived Drug Compounds In VivoSim's NAMkind 3D Tissue Models 
VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test 
VivoSim Labs To Extend Its Human Tissue Platform Beyond Toxicology With Efficacy Testing Services Built On NAMkind Disease Models Of The Liver And Intestine 
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling 
12 Health Care Stocks Moving In Monday's After-Market Session 
Vivosim Labs Notes FDA's Direct Final Rule Clarifying That Non-Animal Methods Can Be Used Where Appropriate For Testing Safety Of Drugs And Biological Products For Human Use 
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods 
VivoSim Labs (NASDAQ:VIVS) vs. iSpecimen (NASDAQ:ISPC) Head to Head Comparison 
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs 
VivoSim Labs Plans To Develop Rat Liver Model To Complement Existing NAMkind Human Liver Platform And Expand Its Liver Toxicology Capabilities
Your note
Sign in to keep a note on VIVS — it syncs with the Stock Master app.